AbbVie Inc. Depreciation & Amortization

Depreciation & Amortization of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Depreciation & Amortization growth rates and interactive chart.


Highlights and Quick Summary

  • Depreciation & Amortization for the quarter ending September 29, 2021 was $2.13 Billion (a -3.32% decrease compared to previous quarter)
  • Year-over-year quarterly Depreciation & Amortization increased by 3.0%
  • Annual Depreciation & Amortization for 2020 was $6.47 Billion (a 220.82% increase from previous year)
  • Annual Depreciation & Amortization for 2019 was $2.02 Billion (a 14.28% increase from previous year)
  • Annual Depreciation & Amortization for 2018 was $1.77 Billion (a 17.59% increase from previous year)
  • Twelve month Depreciation & Amortization ending September 29, 2021 was $8.61 Billion (a -1.88% decrease compared to previous quarter)
  • Twelve month trailing Depreciation & Amortization increased by 33.01% year-over-year
Trailing Depreciation & Amortization for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
$8.61 Billion $8.77 Billion $8.13 Billion $6.47 Billion
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Depreciation & Amortization of AbbVie Inc.

Most recent Depreciation & Amortizationof ABBV including historical data for past 10 years.

Interactive Chart of Depreciation & Amortization of AbbVie Inc.

AbbVie Inc. Depreciation & Amortization for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $2,127.0 $2,200.0 $2,215.0
2020 $2,065.0 $2,292.0 $1,555.0 $559.0 $6,471.0
2019 $509.0 $503.0 $502.0 $503.0 $2,017.0
2018 $442.0 $435.0 $443.0 $445.0 $1,765.0
2017 $369.0 $379.0 $379.0 $374.0 $1,501.0
2016 $328.0 $304.0 $289.0 $268.0 $1,189.0
2015 $261.0 $227.0 $190.0 $158.0 $836.0
2014 $193.0 $192.0 $202.0 $199.0 $786.0
2013 $200.0 $234.0 $236.0 $227.0 $897.0
2012 $309.0 $227.0 $295.0 $319.0 $1,150.0
2011 $324.87 $315.23 $317.61 $314.48 $1,272.0
2010 $1,184.36 $1,184.0

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.